Emergent, Temasek to form flu JV

Emergent BioSolutions Inc. (NYSE:EBS) and Temasek Life Science Ventures will form Epic Bio Pte. Ltd., a JV to develop and commercialize a pandemic vaccine against H5N1 influenza strains. The multivalent, cross-protective vaccine will use multiple antigens from Temasek and be delivered as a single vaccine using Emergent's MVAtor vaccine delivery technology. Clinical testing is expected to begin in 2012. The JV also will develop mAbs to treat pandemic H5N1 influenza using Temasek's monoclonal technology. ...